

Organised by

In Collaboration with















NEW MELA B3 SERUM

NEW SOLUTION

FOR THE MANAGEMENT OF HYPERPIGMENTATION DISORDERS POWERED BY MELASYL™

18 YEARS OF RESEARCH



Distributed by: **APEX PHARMACY MARKETING SDN BHD**No. 2, Jalan SS13/15, 47500 Subang Jaya

Selangor Darul Ehsan, Malaysia

Tel **+603 5629 3688 •** Fax **+603 5636 8025**



MELASYL[™] TRAPS DHI, DHICA, DOPAQUINONE BEFORE THEIR TRANSFORMATION INTO MELANIN

DHI: Dihydroxyindole DHICA: Dihydroxyindole-2-carboxilic acid

 Muller B et al – JEADV 2024 https://doi.org/10.1111/jdv.19910

mported by:

L'ORÉAL MALAYSIA SON BHD

Crown Penthouse, 1 Powerhouse, No. 1, Persiaran Bandar Utama Bandar Utama, 47800 Petaling Jaya, Selangor, Malaysia Tel 1300 22 2232 • Email Customerservice.MY@loreal.com





2-5 October 2024

9 Kuala Lumpur Convention Centre

WELCOME MESSAGE

Dear Colleagues

On behalf of the Organising Committee of the 26th Regional Conference of Dermatology 2024, we would like to cordially invite you – dermatologists, physicians, dermatological practitioners, trainees, medical officers, aesthetic pharmacists and all professionals associated with dermatology - to join us for the 26th Regional Conference of Dermatology on 2-5 October 2024 at the Kuala Lumpur Convention Centre. The Annual Dermatology Conference of the Dermatological Association of Malaysia will be held in conjunction with the 26th RCD 2024. We, of course, welcome the pharmaceutical and biomedical partners to join us for this face-to-face conference as well.

The theme of the 26th RCD is 'Medical & Cosmetic Dermatology: Global Panorama' and will cover the technological advancements and breakthroughs in dermatology, updating the skills in the management of skin diseases and providing an opportunity to meet with the key opinion leaders within the region and internationally.

Renowned and prominent faculty of speakers are being lined up with well-chosen topics to ensure that this conference will be academically fruitful. This would be the perfect opportunity for the fraternity in the region to come together in fellowship and pave the way to enhance cooperation and sharing of experiences and knowledge.

We look forward to welcoming you to Malaysia.



Dr Sabeera Begum Organising Chair, RCD 2024



PDM EXECUTIVE COMMITTEE 2024 - 2026

Associate Professor Dr Tan Wooi Chiang	President
Dr Sabeera Begum	Immediate Past President
Dr Ch'ng Wee Beng, Peter	Vice President
Dr Sharifah Rosniza Syed Nong Chek	Honorary Secretary
Dr Teoh Sze Yuen, Benji	Honorary Treasurer
Dr How Kang Nien	Committee Member
Dr Teeba Raja	Committee Member
Dr Zareen Aidah Yahya	Committee Member
Dr Nirmala Ponnuthurai	Committee Member



RCD ORGANISING COMMITTEE

Dr Sabeera Begum	Organising Chairperson
Associate Professor Dr Tan Wooi Chiang	Scientific Chairperson
Dr Ch'ng Wee Beng, Peter	Secretary
Dr Sharifah Rosniza Syed Nong Chek	Treasurer
Dato' Dr Noor Zalmy Azizan	Social Events
Dr Teoh Sze Yuen, Benji	Social Events
Dr Nazirin Ariffin	Committee Member
Dr Teeba Raja	Committee Member
Dr How Kang Nien	Committee Member



RCD SCIENTIFIC COMMITTEE

Associate Professor Dr Tan Wooi Chiang	Scientific Chairperson
Associate Professor Dr Foong Boon Bee, Henry	Dermatology Chapter
Dato' Dr Noor Zalmy Azizan	Dermatopathology
Dr Leong Kin Fon	Pediatrics Dermatology
Dr Ch'ng Wee Beng, Peter	Aesthetic Medicine
Dr Sharifah Rosniza Syed Nong Chek	Nursing
Dr How Kang Nien	Abstract Chairperson
Dr Tang Min Moon	Abstract Committee
Dr Tang Jyh Jong	Abstract Committee



APEX PHARMACY MARKETING SDN BHD

No. 2, Jalan SS13/15, 47500 Subang Jaya Selangor Darul Ehsan, Malaysia Tel +603 5629 3688 • Fax +603 5636 8025

L'ORÉAL MALAYSIA SDN BHD

Crown Penthouse, 1 Powerhouse, No. 1, Persiaran Bandar Utama Bandar Utama, 47800 Petaling Jaya, Selangor, Malaysia Tel 1300 22 2232 • Email Customerservice.MY@loreal.com



FACULTY

Australia

John Su

India

M Raman Sandipan Dhar

Indonesia

Linda Astari Sondang Amelia P. Sirait Sri Awalia Febriana Yulianto Listiawan Srie Prihianti Gondokaryono

Japan

Akimichi Morita

Korea

Sook Jung Yun

Philippines

Bryan Guevara Maria Jasmin Jacinto Jamora Peachy Lao Teresita Gabriel Maria Franchesca S Quinio-Calayag

United Kingdom

Eduardo Calonje Jonathan Barker Richard Barlow

United States of America

Amy Paller Henry Lim Phyu Aung

Hong Kong

David Luk Chi Kong

Vietnam

Pham Thi Uyen Nhi

Malaysia

Abu Qkhurairah Jefri Adawiyah Jamil Amir Hamzah Mohd Nor Suhaimi Azura Mohd Affandi Chang Choon Chor Ch'ng Chin Chwen Choon Siew Eng Evelyn Yap Wen Yee Felix Yap Boon Bin Gangaram Hermandas Harikrishna KR Nair Heah Sze Shu Henrietta Albela Henry Foong Boon Bee Ikmal Hisyam Jenny Tan Yen Ling Kwan Zhenli Lalitha Pillay B Gopinathan Latha Selvarajah Lee Bang Rom Lee Wai Quen Leong Kin Fon Michelle Voo Sook Yee Mimi Wong Hoi Ling Ng Su Yuen Nirmala Ponnuthurai Oh Hoey Hoey Ooi Shin Yi Roskasmini Abdullah Siti Amalina Mazlan Siti Nuraihan Nordin Syahrul Sazliyana Tang Jyh Jong Tang Min Moon Zuliatul Faizah Lee Wai Quen Noor Zalmy Azizan Peter Ching Wee Beng Teeba Raja

Tan Wooi Chiana Sharifah Rosniza Syed Nong Chek

South Africa

Wayne Grayson

Taiwan

Patrick Huang Po-Han Wu Yu Hung Tsai Tsen-Fang Chung Wen Hung

Thailand

Chanat Kumtornrut Charussri Leeyaphan Nopadon Noppakun Pravit Asawanonda Rataporn Unapakom Tanonakiet Tienthavorn Vasanop Vachiramon Rossaphorn Kittiyaowamarn

Singapore

Angeline Yong Anning Lim Yen Loo Goh Chee Leok Joyce Lim Tena Ee Mark Koh Jean Aan Oh Choon Chiat Steven Thng Tan Suat Hoon Tay Yong Kwang Tee Shang Ian Lee Haur Yueh Lim Chay Mien Soh Yoke Teng Vanessa Sharon Maria

United Arab Emirates

Jawaher Abdullah Alnaqbi



PROGRAMME SUMMARY

DATE TIME	3 RD OCT 2024 [THURSDAY]	4 TH OCT 2024 [FRIDAY]	5 [™] OCT 2024 [SATURDAY]
0700 - 0730		REGISTRATION	
0730 - 0745			
0745 - 0800	MEET-THE-EXPERTS (1 – 3)	FREE PAPER PRESENTATIONS	FOCUS SESSIONS
0800 - 0815	(Q & A)	(1 – 3)	(1 – 3)
0815 - 0830	No. No. of Contract of Contrac		
0830 - 0845			
0845 - 0900	SYMPOSIA	SYMPOSIA	SYMPOSIA
0900 - 0915	(1 – 3)	(10 – 12)	(21 – 24)
0915 - 0930	(Q & A)	(Q & A)	(Q & A)
0930 - 0945			
0945 - 1000	TEA BREAK		
1000 - 1015	TEA BREAK	PLENARY 2	PLENARY 3
1015 - 1030			
1030 - 1045	OPENING	ТЕА В	DEAV
1045 - 1100	CEREMONY	TEA D	NLAN
1100 – 1115			
1115 – 1130		SYMPOSIA	SYMPOSIA
1130 - 1145	PLENARY	(13 – 15)	(25 – 27)
1145 – 1200	1	(Q & A)	(Q & A)
1200 – 1215			



2-5 October 2024

Kuala Lumpur Convention Centre

PROGRAMME SUMMARY

CONTINUED

DATE TIME	3 RD OCT 2024 [THURSDAY]	4 [™] OCT 2024 [FRIDAY]	5 TH OCT 2024 [SATURDAY]
1230 - 1245	PRE-LUNCH	PRE-LUNCH	PRE-LUNCH
1245 - 1300	SYMPOSIA	SYMPOSIA	SYMPOSIA
1300 – 1315	(1 - 3)	(4 – 6)	(7 – 9)
1315 – 1330			
1330 - 1345	LUNCH	LUNCH	LUNCH
1345 - 1400	SYMPOSIA (1 – 3)	SYMPOSIA (4 – 6)	SYMPOSIA (7 – 9)
1400 - 1415			
1415 – 1430			
1430 - 1445	SYMPOSIA (4 – 6)	SYMPOSIA (16 – 18)	SYMPOSIA (28 – 30)
1445 - 1500	(Q & A)	(Q & A)	(Q & A)
1500 - 1515	13.20	100	754
1515 - 1530	вмі	ВМІ	BMI
1530 - 1545	(1 – 3)	(4 – 6)	(7 – 9)
1545 - 1600		TEA BREAK	
1600 - 1615			
1615 – 1630	SYMPOSIA	SYMPOSIA	SYMPOSIA
1630 - 1645	(7 - 9)	(19 – 21)	(31 – 33)
1645 - 1700	(Q & A)	(Q & A)	(Q & A)
1700 – 1715			

GALDERMA

EST. 1981

ADVANCING DERMATOLOGY FOR EVERY SKIN STORY





Restylane

DERMATOLOGICAL
SKINCARE BRAND*

** TOPICAL ACNE TREATMENT FOR THE FACE & TRUNK

24/7 456 DAYS OF HEALTHY GLOW²



Galderma Malaysia Sdn. Bhd. (Co. No: 201801029950 (1291976-D)) Unit 904, Level 9, Uptown One, Jalan SS21/58, Damansara Utama, 47400 Petaling Jaya, Selangor Darul Ehsan, Malaysia. *Source: Based on internal analysis by Galderma Malaysia SDN BHD using data from the following source: IQVIA Malaysia National Sales Audit (NSA), sell-in sales units and values, total markets of ATC2 = D02 - EMOLLIENTS & PROTECTIVES category, for the period MAT Q4 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. References: 1. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 µg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699. 2. Wu Y et al. J Cosmet Dermatol 2020;19(7):1627-1635. Document No.: MY-AFC-2400010 Production Date: Sept 2024 FOR HEALTHCARE PROFESSIONAL USE ONLY.



SCIENTIFIC PROGRAMME

	Registration		
7:30 - 08:30	Conference Hall 2	Conference Hall 1	Conference Hall 3
7:30 - 08:30	Meet the experts 1 Optimizing the Management of Plaque Psoriasis: Insights from Experts Chairpersons: Choon Siew Eng Welcome and Introduction Choon Siew Eng Current Medical Treatment Modalities for Psoriasis Jonathan Barker Integrating Lifestyle Modifications into Psoriasis Management Pravit Asawanonda Patient Education and Empowerment in Psoriasis Care Jonathan Barker	Meet the experts 2 Atopic Dermatitis Chairperson: Jenny Tan Yen Ling Leong Kin Fon Updates in Pathogenesis and Treatment of Severe Atopic Dermatitis Amy Susan Paller Update on Itch Mechanism in Atopic Dermatitis Leong Kin Fon Roles of Food Allergy among AD Patients Jenny Tan Yen Ling	Meet the experts 3 CPC Chairperson: Lee Bang Rom Wu Yu Hung Panelist: Eduardo Calonje Wayne Grayson



SCIENTIFIC PROGRAMME

Time	Session		
08:40 - 09:40	Symposium 1 Drug Hypersensitivity Chairperson: Lim Yen Loo Tang Min Moon Delabelling Penicillin Allergy: How do I do it? Lim Yen Loo NSAIDs Hypersensitivity: How do I manage? Tang Min Moon HLA-typing in SCARs: What is Important? Chung Wen-Hung	Symposium 2 Psoriasis and Ichthyotic Disorders Chairperson: Henrietta Albela Lalitha Pillay B Gopinathan Update in the Treatment of Childhood Psoriasis: Treat Early or Hit Later Sandipan Dhar Updates in Management of Congenital Ichthyosis Henrietta Albela Interesting Cases from Our Pediatric Clinic – Papulosquamous and Ichthyotic Disorders Lalitha Pillay B Gopinathan	Symposium 3 Inflammatory Dermatoses Chairperson: Tee Shang Ian Zuliatul Faizah Approach to Lichenoid Dermatosis Lee Bang Rom Approach to Eosinophilic Dermatitis Nopadon Noppakun Vesiculobullous Disorders Maria Jasmin Jacinto Jamora
09:40 - 09:50	Q&A		
09:50 - 10:20	Tea Break		
10:20 - 11:20	Opening Ceremony		
11:20 - 12:30	John C Su	g the Potentials, Navigating the diated photodermatoses, photo	



SCIENTIFIC PROGRAMME

Time	Session		
12:30 - 13:15	Special Highlights from ILDS ILDS and Global Dermatology Henry Lim	Pre-Lunch Symposium 2 by GSK Chairperson: Pubalan A/L Muniandy The Time is Now: Unveiling and Launching the Next- Gen Herpes Zoster Vaccine: Shingrix Peter Weissnsee	Pre-Lunch Symposium 3 by Sanofi Chairperson: Norazirah binti Md Nor Prurigo Nodularis and Atopic Dermatitis: Distinct Diseases With Shared and Unique Roles for Type 2 Inflammation Saeko Nakajima
13:15 - 14:15	Lunch Symposium 1 by L'Oréal Chairperson: Peter Ch'ng Wee Beng Innovation In Pigmentary Disorders: A Dermatology Update With Latest Clinical Study Results. Pigmentary Disorder In Asia: Epidemiology And Clinical Management Challenges Angeline Yong Anning The Science Behind Correcting Pigmentation Disorders: Introducing Melasyl, The Latest Patented Innovation Angeline Tay Mei Ee Topical Management For hyperpigmentary disorders: A novel molecule with unique mode of action. Clinically proven efficacy from randomized controlled	Lunch Symposium 2 by Beiersdorf Chairperson: Azura Mohd Affandi Launch of Eucerin ProAcne Adjunctive Soothing Care, Integrating Dermocosmetics into Acne Management: Evidence-Based Strategies and Clinical Insights Overview of Acne Latha Selvarajah Role of Dermocosmetics in the management of Acne Evelyn Yap Wen Yee How to intergrate Eucerin Products into Acne Care Kwan Zhenli	Lunch Symposium 3



SCIENTIFIC PROGRAMME



SCIENTIFIC PROGRAMME

16:15 - 17:15	Symposium 7	Symposium 8	Symposium 9
	Nail	Benign and Malignant	Cutaneous Lymphoma
	Chairperson:	Skin Tumors	and Other Neoplasm
	Ch'ng Chin Chwen	Chairperson:	Chairperson:
	Rataporn Ungpakom	Lee Wai Quen	Dawn Angelia Ambrose
	■ ONYCHOMYCOSIS: Then	Mimi Wong Hoi Ling	Sook Jung Yun
	and Now	= Histiocytosis:	≈ Cutaneous CD30+
	Rataporn Ungpakom	Langerhan and Non	Lymphoproliferative
	Melanonychia: How to	Langerhan	Disorders
		Ng Su Yuen	Tan Suat Hoon
	Distinguish a Malignant	S 5. 19 5.	
	Condition from a Benign	Cutaneous Lymphoma	Interesting Cutaneous
	One	in Children	Lymphoma Cases
	Oh Choon Chiat	Mimi Wong Hoi Ling	Eduardo Calonje
	Nail Cosmetics: A	Interesting Lumps &	 Spindle Cell Vascular
	Dermatologist's Point of	Bumps in Pediatric	Neoplasm
	View	Clinic	Ikmal Hisyam
	Ch'ng Chin Chwen	Lee Wai Quen	



Gain more insights from the experts at Boehringer Ingelheim-sponsored Pre-Lunch symposium

Navigating **Generalized Pustular Psoriasis (GPP)**Management - "Target to Treat"

4th October 2024 (Fri) 1225 - 1310

Conference Hall 2, Kuala Lumpur Convention Centre, Malaysia.







For healthcare professionals only.





SCIENTIFIC PROGRAMME

07:00 - 07:30	Registration			
07:30 - 08:30	Conference Hall 2	Conference Hall 1	Conference Hall 3	
07:30 - 08:30	Free Paper Presentation 1	Free Paper Presentation 2	Free Paper Presentation 3	
08:30 - 09:30	Symposium 10 The Complete Guide to GPP: From Immunology to Treatment Goals Chairperson: Akimichi Morita Welcome and Introduction Akimichi Morita Understanding GPP Immunology and Inflammation Jonathan Barker Challenges in Diagnosing and Assessing GPP Choon Siew Eng GPP: Evidence to Guide Treatment Goals and Pathway Tsai Tsen-Fang	Symposium 11 Genodermatoses Chairperson: Ellis Hon Oh Hoey Hoey Roles of Genetic Testing in Practical Dermatology Mark Koh Jean Aan Updates in Management of Epidermolysis Bullosa Srie Prihianti Gondokaryono Interesting Cases From Our Genodermatosis Clinic Oh Hoey Hoey	Symposium 12 Infections Chairperson: M Ramam Phyu Aung Diagnostic Pitfalls in Cutaneous Infectious Diseases Wayne Grayson Histopathology of Leprosy and Tuberculosis: An Overview Zuliatul Faizah Atypical Mycobacteria Infection: Diagnostic Difficulties Sondang Amelia P Sirait	



SCIENTIFIC PROGRAMME

09:40 - 10:50	Plenary 2 Chairperson:			
	Choon Siew Eng			
	Poonnawis Sudtikoonaseth			
	■ What Monogenic Disorders Teach About Common Disorders			
	Amy Susan Paller		**	
	Clinicopathological Correl	ation in Dermatonathology		
	Eduardo Calonje	adon in Definition participation by		
10:50 - 11:15	Tea Break			
11:15 - 12:15	Symposium 13	Symposium 14	Symposium 15	
	Inpatient Dermatology 1	Neonatal Dermatology	Melanocytic and	
	Chairperson:	Chairperson:	Pigmentary Disorders	
	Evelyn Yap Wen Yee Lee Haur Yueh	Heah Sze Shu	Chairperson:	
		Nirmala Ponnthurai	Maria Jasmin Jacinto Jamor	
	An Updated Review of	Birthmarks: What, Why,	Noor Zalmy Azizan	
	Pemphigus Diseases	When and How? Nirmala Ponnthurai	How to practically	
			approach diagnosis of	
	Advancements in	Update in Management	Melanocytic lesions Phyu Aung	
	Bullous Pemphigoid	of Mosaic Rasopathies:	E WEST N	
	Management Lee Haur Yueh	Melanocytic, Sebaceous	 Acral Melanomas Sook Jung Yun 	
		& Epidermal Heah Sze Shu	750	
	Vasculitis or Vascular attended Vascular attended Vascular attended Vascular attended Vascular attended Vascular attended		= Clinico-Pathological	
	Vasculopathy: How to	Interesting Cases from Neonatal Ward: Pod	Correlations in	
	Differentiate & Manage Them?	Neonatal Ward: Red, Orange and Green	Pigmentary Disorders M Ramam	
	Evelyn Yap Wen Yee	Siti Nuraihan Nordin		
	(4)	3.		



SCIENTIFIC PROGRAMME

Time	Session		
12:25 - 13:10	Pre-Lunch Symposium 4 by Boehringer Ingelheim Navigating GPP Management – "Target to Treat" Akimichi Morita Welcome and Introduction Azura Mohd Affandi Unravelling to the Role of IL-36 in GPP Choon Siew Eng GPP Treatment Approaches & Japan's Experience with IV Spesolimab Akimichi Morita Panel Discussion	Pre-Lunch Symposium 5	Pre-Lunch Symposium 6
13:10 - 14:10	Lunch Symposium 4 by Galderma Chairperson: Leong Kin Fon Real-World Experience with Trifarotene in Acne Patients Bryan Guevara Experts consensus on holistic skincare routine in Acne, Atopic Dermatitis and Sensitive Skin Syndrome Goh Chee Leok	Lunch Symposium 5	Lunch Symposium 6 by Pfizer Chairperson: Peter Ch'ng Wee Beng New Frontier in Management of AD: Strategic Implementation of JAk and Their Appropriate Clinical Context Lee Haur Yueh



SCIENTIFIC PROGRAMME



SCIENTIFIC PROGRAMME

Symposium 19 Contact Dermatitis Chairperson: How Kang Nien Sharifah Rosniza Syed Nong Chek Hands Contact Eczema: The Patterns and The Implicated Culprits Sri Awalia Febriana Allergic Contact Dermatitis in the SEA Region: A Comparison with the West Goh Chee Leok Contact Dermatitis of the Lips and Oral Mucosa: What is Important? Sharifah Rosniza Syed Nong Chek	Symposium 20 Laser/EBD Chairperson: Nazirin Ariffin Patrick Huang Po-Han Combination of Energy- Based Device and Injectibles: When and How Vasanop Vachiramon Skin Tightening: Facts and myths Patrick Huang Po-Han Procedural Management for Melasma Vasanop Vachiramon	Symposium 21 Neglected Tropical Diseases Chairperson: Benji Teoh Michelle Voo Sook Yee Towards Zero Leprosy Interruption of Transmission and Elimination of Leprosy Michelle Voo Sook Yee Mycetoma Linda Astari Non Tuberculous Mycobacterium infection Charussri Leeyaphan
---	---	---



IF YOU CAN PREVENT SHINGLES SUFFERING, WHY WOULDN'T YOU?1

INDICATIONS

Shingrix is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in



Adults 50 years of age or older¹



Adults 18 years of age or older at increased risk of HZ¹



NOW APPROVED IN MALAYSIA

YOU CAN NOW PROTECT YOUR PATIENTS WITH SHINGRIX.



MSIDC and CDC recommends vaccinating your patients ≥ 50 years with 2 doses of SHINGRIX.^{2,4}



Protection that lasts. SHINGRIX offers 97% efficacy to adults ≥ 50 years, and 91% to adults ≥ 70 years. 1*



Established safety profile. Most vaccination reactions were mild to moderate, with a median duration of 2 - 3 daus.³¹



SHINGRIX is given as a 2-dose series. For ≥ 50 years old, 2^{nd} dose should be administered 2 months after 1^{st} dose. If flexibility is necessary, it can be administered between 2-6 months after.

VACCINATE NOW FOR PROTECTION THAT LASTS UP TO 10 YEARS¹



Median follow-up period of 3.1-4 years in ZOE-50/70.7 * 97.2% (95% CI: 93.7; 99.0) VE against confirmed shingles in subjects \geq 50 years in ZOE-50, 91.3 (95% CI: 86.8; 94.5) VE against confirmed shingles in subjects \geq 70 years in pooled data from ZOE-50 and ZOE-70.1 † Median duration of 3 days or less for local symptoms and 2 days or less for general symptoms.3

References: 1. Shingrix Prescribing Information. 2. Centers for Disease Control and Prevention. Shingles vaccination. Reviewed May 8, 2023. Accessed May 8, 2024. https://www.cdc.gov/vaccines/vpd/shingles/public/Shingrix/index.html. 3. López-Fauqued M, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine. 2019;37:2482-93. 4. Guideline for Adult Immunization - 3rd Edition, Malaysia Society of Infectious Diseases and Chemotherapy (Published in October 2020, Revised in November 2023), Page 187.

For Malaysia Healthcare Professionals Only Adverse events should be reported to drugsafetyinfo.my@gsk.com

Trade marks are owned by or licensed to the GSK group of companies.

© 2024 GSK group of companies or its licensor.

GlaxoSmithKline Pharmaceutical Sdn Bhd 19561000141 (3277-U) HZ.01, Horizon Penthouse, 1 Powerhouse, 1, Persiaran Bandar Utama, Bandar Utama, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia. Tel: (603) 2037 9808 www.my.gsk.com Before prescribing, please refer to the full prescribing information, which is available via scanning this QR code.

For any issues accessing the prescribing information via QR code please contact GSK Malaysia at medinfo.my@gsk.com.

PM-MY-SGX-LBND-240007 09/24





SCIENTIFIC PROGRAMME

Time	Session		
07:00 - 07:30	Registration		
	Conference Hall 2	Conference Hall 1	Conference Hall 3
07:30 - 08:30	Focus Session 1 Eczema & Prurigo Chairperson: Adawiyah binti Jamil Felix Yap Boon Bin Recognition and Diagnosis of Light Sensitivity in AD Henry Lim Prurigo Nodularis: An Update on the Pathogenesis and Treatment Felix Yap Boon Bin Atopic Dermatitis and Psoriasis Overlap Syndrome: New entity or under-recognize variant? Adawiyah binti Jamil	Focus Session 2 What is New? Chairperson: Melinda Tong Emerging and Combination Therapy for Hairloss Angeline Yong Anning Skin Booster: What's the Boost? Peter Ch'ng Wee Beng Laser Failures – Lessons Learnt Peter Ch'ng Wee Beng	Focus Session 3 Bits and Pieces Chairperson: Leong Kin Fon Nazirin Ariffin Photography in Dermatology Leong Kin Fon Establishing A Viable Research System in Dermatology Steven Thng Tien Guan Predatory Journals and Publishers Kwan Zhenli



SCIENTIFIC PROGRAMME

Time	Session		
08:30 - 09:30	Symposium 22 STI/HIV Chairperson: Linda Astari Pubalan A/L Muniandy Navigating Mucocutaneus Diseases in HIV/AIDS Linda Astari The Syphilis Skyrocket - What Should Dermatologists Do? Rossaphorn Kittiyaowamarn Stopping HIV and STIs in a New Era of Care: The Promise of PEP & PrEP Teresita Gabriel	Symposium 23 Injectables Chairperson: Priya Gill A/P Amar Singh Gill Tanongkiet Tienthavorn HA vs Non-HA Fillers Peachy Lao Facial Rejuvenation and Augmentation with Biostimulators: Technique and Outcomes Tanongkiet Tienthavorn Natural Looking Lip Fillers: How to Achieve It Pham Thi Uyen Nhi	Symposium 24 Skin Cancer Chairperson: Azura Mohd Affandi Latha Selvarajah Treatment for NMSC: Past, Present and the Future Azura Mohd Affandi Chemoprevention in Skin Cancer Medicine Kwan Zhenli Clinical Decision Making in Melanoma: How to Treat in 2024? Richard Barlow
09:30 - 09:40	Q&A		
09:40 - 10:50	Plenary 3 Chairperson: Goh Chee Leok Tran Hau Khang Supplements and the Skin: Harmful, Helpful, or Placebo? Peachy Lao Evolution of Fractional Photothermolysis for Skin Rejuvenation Peter Ching Wee Beng		
10:50 - 11:15	Coffee Break		



SCIENTIFIC PROGRAMME

11:15 - 12:15	Symposium 25 Acne, Rosacea & HS Chairperson: Chanat Kumtornrut Chang Choon Chor Recognizing Photoallergy, Phototox HS: New Insights Into Disease Mechanism And An Evolving Treatment Landscape Tan Wooi Chiang Optimizing Outcomes for Rosacea: Current and Emerging Treatment Strategies Chanat Kumtornrut Recent Advances in Management of Acne Vulgaris Chang Choon Chor	Symposium 26 Laser Chairperson: Henry Foong Boon Bee Joyce Lim Teng Ee How I manage Acne scars Joyce Lim Teng Ee Melasma: LIGHTS At The End of The Tunnel Henry Foong Boon Bee Laser Skin Resurfacing: Benefits, Side Effects, and Peachy Lao	Symposium 27 Wound Care Chairperson: Noor Zalmy Azizan Ooi Shin Yi Diagnostic and Therapeutic Principles of Chronic Wound Noor Zalmy Azizan Wound Healing: Potential Therapeutic Options Harikrishna KR Nair Tips and Tricks in Woun Management Ooi Shin Yi



SCIENTIFIC PROGRAMME

Time	Session
12:25 - 13:10	Dermatology Chapter College of Physicians, AMM Symposium The Most Fascinating Cases From Our Clinics In 2024 Chairperson: Henry Foong Boon Bee Latha Selvarajah
	Bullous Pemphigoid and Omalizumab Rebecca Choong Kai Jan
	 Secukinumab In Netherton Syndrome Henrietta Albela
	 A case series of Anifrolumab for treatment of cutaneous lupus erythematosus Elizabeth Chang Wei Hsi
	From Clinical Dermatology To Investigative Dermatology: Where We Have Come From Evelyn Yap Wen Yee Latha Selvarajah
13:10 - 14:10	Dermatology Chapter College of Physicians, AMM Symposium
	The Interesting Cases From Our Dermatology Wards 2024
	Giant Congenital Melanocytic Nevus: Excision Or Observation Reyhanah Mohd Rashid Vaishnavi a/p Nadesonmulu Vaishnavi a/p Nadesonmulu
	 Combination Therapy In Complex Vascular Malformations: Success Stories Reyhanah Mohd Rashid Tan Yuong Chin
	Metamorphosis Of A Dermatologist To A Paediatric Dermatologist: Ten Essential Ingredients Leong Kin Fon
	How To Equip A Medical Dermatologist With Aesthetic Skills Henry Foong Boon Bee



SCIENTIFIC PROGRAMME

Time	Session		
14:10 - 15:10	Symposium 28 What is new? Chairperson: Kwan Zhenli Nazirin Ariffin The Microbiome in Dermatology and Cosmetology Chanat Kumtornrut Biological Agents in Cutaneous Lupus Erythematosus: Now and the Future Syahrul Sazliyana Syahrul Sazliyana CADR to Immuno- modulators Latha Selvarajah	Symposium 29 Injectables Chairperson: Pham Thi Uyen Nhi Ruban Satkuna Nathan Jawline Contouring: Botulinum Toxin or Fillers Pham Thi Uyen Nhi The Art of Rejuvenation with Combination of Toxin & Dermal Fillers Tanongkiet Tienthavorn Complications of fillers and can you be the savior? Joyce Lim Teng Ee	Symposium 30 Nursing Interventions in Dermatological Emergencies Chairperson: Lim Chay Mien SJS/TEN Lim Chay Mien Erythroderma Lim Chay Mien Staphylococcal Scalded Skin Syndrome Roskasmini Abdullah Vasculitis Siti Amalina Mazlan
15:10 - 15:20	Q&A		
15:20 - 15:50	BMI 7 Tea Symposium	BMI 8 Tea Symposium	BMI 9 Tea Symposium
15:50 - 16:15	Coffee Break		



SCIENTIFIC PROGRAMME

Time	Session		
16:15 - 17:15	Symposium 31 Connective Tissue Disorders Chairperson: Evelyn Yap Wen Yee Teeba Raja Chronic Urticaria & Angioedema: Recent Advances Adawiyah binti Jamil Dermatomyositis: Clinicoserological Approach and Management Evelyn Yap Wen Yee Sclerosing Dermatoses: The Past and The Present Teeba Raja	Symposium 32 Stretch Mark, Keloids & Vascular lesions Chairperson: Joyce Lim Teng Ee Gangaram Hemandas Latest Treatment Of Stretch Marks Fr A Plastic Surgeon Point Of View Wan Syazli Rodzaian Wan: Ahmad Treating Striae Distensae Alba with calcium hydroxyapatite and Microfocused Ultrasound Joyce Lim Teng Ee My Personal Journey using vascular laser Gangaram Hemandas	Symposium 33 Procedures in Dermatology Chairperson: Sharifah Rosniza Syed Nong Chek Slit-skin Smear in Leprosy Amir Hamzah Mohd Nor Suhaimi Lasers in Dermatology: Paramedics Perspective Abu Qkhurairah Jefri Cryotherapy for Benign Skin Lesions Soh Yoke Teng Phototherapy: Singapore Experience Vanessa Sharon Maria
17:15 - 17:25	Q&A		
17:25 - 17:40	Closing Ceremony		



2-5 October 2024

Kuala Lumpur Convention Centre

ACKNOWLEDGEMENT

Diamond

L'ORÉAL

GALDERMA

Platinum







Gold









Bronze

















































MEDICAL & COSMETIC DERMATOLOGY: GLOBAL PANORAMA

SHINGLES PREVENTION:

THE TIME IS NOW

A SPECIAL LAUNCH EVENT FOR DERMATOLOGIST

The Time is Now: Unveiling and Launching the Next-Gen Herpes Zoster Vaccine: Shingrix

3rd Oct 2024 (Thurs) | 12:30 pm - 1:15 pm KLCC Conference Hall 1, Pre-Lunch Symposium 2, GSK

Dr. Peter Weisenseel

Senior Doctor and Head of the Department for Clinical Research, Dermatologikum Hamburg, Germany

Dr. Peter Weisenseel, based at Dermatologikum Hamburg in Germany, is a seasoned Senior Doctor and the Head of the Department for Clinical Research since 2018, he has held key positions in renowned institutions, including being the Head of Medical Affairs at SCIderm/TFS GmbH and Medical Development Manager at Janssen-Cilag GmbH.

He has a wealth of experience in chronic inflammatory skin diseases, ranging from psoriasis and atopic dermatitis to acne and rosacea. Dr. Weisenseel expertise extends to clinical study management, where he has played pivotal roles in over 65 clinical studies focusing on systemics and biologics for psoriasis and atopic dermatitis.

Before prescribing, please refer to the full prescribing information, which is available via scanning this QR code. For any issues accessing the prescribing information via QR code, please contact GSK Malaysia at medinfo.my@gsk.com. Adverse events should be reported to drugsafetyinfo.my@gsk.com
Trade marks are owned by or licensed to the GSK group of Companies

2024 GSK group of companies or its licensor.



For Malaysia Healthcare Professionals Only


This educational program is sponsored by GSK.





ACHIEVE LASTING CHANGE





RAPID AND SUSTAINED CONTROL - CONSISTENT ACROSS ALL AGES

Sustained improvement of itch, skin clearance, and QoL up to 52 weeks, with rapid control after first dose¹⁻¹⁶

UNIQUE LONG-TERM SAFETY PROFILE

- With 5 years long-term safety data in adults¹⁷
- Approved in patients as young as 6 months¹

START WITH EASE, STAY WITH CONFIDENCE

- » DUPIXENT is not an immunosuppressant¹
- » 87% Adult patient satisfaction with DUPXIENT treatment at 3 years¹⁸

~38,075 PATIENTS TREATED WITH DUPIXENT IN RWE STUDIES¹⁹

For the full prescribing information, please scan the QR Code or visit the link provided. Full prescribing information is also available upon request from:



DUPIXENT MY PI https://surl.sanofi.com/dupixentmy

Sanofi-Aventis (Malaysia) Sdn Bhd (334110-P), Unit TB-18-1, Level 18, Tower B, Plaza 33, No. 1 Jalan Kemajuan, Seksyen 13, 46200 Petaling Jaya, Selangor Darul Ehsan, Malaysia. Tel: 03 7651 0800, Fax: 03 7651 0805.



DUPIXENT SG PI https://surl.sanofi.com/dupixentsg

Sanofi-Aventis Singapore Pte Ltd, 38 Beach Road #18-11, South Beach Tower, Singapore 189767. Tel: 65 6226 3836, Fax: 65 6535 5836.



QoL, quality of life: RWE, real-world experience.

References: 1. DUPIXENT Singapore Prescribing Information, July 2023 and Malaysia. October 2023. 2. Blauvelt A et al. Lancet 2017; 389:2287-2303. 3. Data on file (AD-1224 CSR). Sanoti and Regeneron Pharmaceuticals, Inc. 2016. 4. Blauvelt A et al. Lancet 2017; 389:2287-2303. [suppl.] 5. Data on file (AD-1224 CSR). Sanoti and Regeneron Pharmaceuticals, Inc. 2018. 6. Data on file (AD-1652 CSR EAS). Sanoti and Regeneron Pharmaceuticals, Inc. 2019. 8. Politer AS et al. Jan Acad Dermatol 2020; 83(3):1282-1293. 9. Cork MJ et al., Poster presented at the Revolutionizing Atopic Dermatilis Conference. 2021. June 13: Virtual Conference. Poster 468
10. Data on file (AD-1652 CSR prurius NRS). Sanoti and Regeneron Pharmaceuticals, Inc. 2019. 11. Singson EL et al. June 4. Am J Clin Dermatol 2020; 15(1):44-56. 12. Data on file (AD-1652 CSR EAS). Sanoti and Regeneron Pharmaceuticals, Inc. 2019. 13. Pailer AS et al. June 14. Virtual Conference. 2021. June 15. Virtu

For Healthcare Professionals only

